Nasdaq
$11.80▼ 2.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $170.2MShares out 14.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 3d agoPre-market26.10.22 20:048-KKey event#●●●#●●●
Korro Bio, Inc.Bullish
Korro Bio announced positive preclinical results for its AATD treatment candidate, KRRO-111, demonstrating over 95% mRNA editing efficiency and a 95% reduction in toxic Z-AAT protein in mouse models. The company expects to submit a regulatory application for clinical trials in the first half of 2027.…more
$11.80-2.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:108-KKey event
Korro Bio, Inc.
Korro Bio has initiated dosing for the first cohort in its Phase 1/2 clinical trial (ANCHOR) of KRRO-121, a candidate for treating hyperammonemia. The trial is currently evaluating safety and pharmacokinetics in healthy volunteers, with patient dosing expected in the first half of 2027 and interim results anticipated in the second half of 2027.…more
$11.80-2.03%vs prev closeView filingShare - 9.15After-hours26.09.16 05:154Ownership
Korro Bio, Inc.
Korro Bio insider Jean-Francois Formela reported a change in his beneficial ownership of company shares as of September 11, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock holdings.…more
$11.80-2.03%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 20:11#●●●#●●●
Korro Bio Reports Positive Preclinical Data for AATD Candidate KRRO-111…more
Korro Bio announced that its KRRO-111 candidate demonstrated potential to treat both lung and liver manifestations of AATD in preclinical studies. Regulatory submission for the program is anticipated in the first half of 2027.…more
$11.80-2.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.16After-hours26.10.17 05:05
●●●●●●●● ●●●●● ●●●●●●
Korro Bio has granted stock options for a total of 4,000 shares to two newly hired employees. This is a standard inducement grant for talent acquisition under Nasdaq listing rules and does not have a material impact on the company's financial position.…more
$11.80-2.03%vs prev close - 10.5After-hours26.10.06 05:05
●●●●●●●● ●●●●● ●●●●●●
Korro Bio has dosed the first cohort in its Phase 1/2 clinical trial for KRRO-121, a treatment candidate for urea cycle disorders. The company expects to begin dosing patients in the first half of 2027 with interim results anticipated in the second half of the year.…more
$11.80-2.03%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report